A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Completed
MedImmune LLC
Phase 2
2012-02-27
The overall purpose of the study is to determine if MEDI-551, when used in combination with
salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine
(DHAP) in patients with relapsed or refractory DLBCL who are eligible for Autologous Stem
Cell Transplant (ASCT), has superior efficacy compared to rituximab in the same population.
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
Completed
MedImmune LLC
Phase 2/Phase 3
2015-04-01
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an
neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in
participants with NMO/NMOSD.
Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
Suspended
Viela Bio
Phase 2
2019-12-27
Viela Bio is conducting an open-label, randomized study of inebilizumab, VIB4920, or the
combination as part of a multi-center study in highly sensitized patients on the deceased
donor waiting list for kidney transplantation. Eligible subjects will be randomized to one of
three treatment arms, administered the investigational products as an intervention and
subsequently followed for safety.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
